The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Alnylam Pharmaceuticals Inc shares valued at $8,300,070 were purchased by Reitan Colleen F on Sep 09 ’25. At $461.12 per share, Reitan Colleen F acquired 18,000 shares.
Also, Tanguler Tolga sold 3,474 shares, netting a total of over 1,557,649 in proceeds. Following the sale of shares at $448.37 each, the insider now holds 25,992 shares.
Before that, Tanguler Tolga had added 3,474 shares to its account. In a trade valued at $1,571,012, the Officer bought Alnylam Pharmaceuticals Inc shares for $452.22 each.
As published in a research note from Wolfe Research on August 04, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been rated up from an Underperform to a Peer perform. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early August. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] plunged -2.66% to $469.31. The stock’s lowest price that day was $461.47, but it reached a high of $480.045 in the same session. During the last five days, there has been a surge of approximately 4.89%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 90.17%. Shares of the company reached a 52-week high of $484.21 on 09/09/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 460.51, which, if violated, would cause prices to drop to 451.70. In the upper region, resistance lies at 479.08. The next price resistance is at 488.85. RSI (Relative Strength Index) is 67.35 on the 14-day chart, showing neutral technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-15 jumping by 47400.0 shares to 3.43 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 3.38 million shares. A jump of 1.38% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.75 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.75.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 377.5 in the next 12 months, down nearly -21.7% from the previous closing price of $482.13. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 470 by 2025, with the lowest price target being 338. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $353.
